Search

Your search keyword '"Porembka, Matthew R."' showing total 396 results
Start Over Author "Porembka, Matthew R."
396 results on '"Porembka, Matthew R."'

2. Correction to: Lenvatinib inhibits the growth of gastric cancer patient‑derived xenografts generated from a heterogeneous populations

Author

Karalis, John D., Yoon, Lynn Y., Hammer, Suntrea T. G., Hong, Changjin, Zhu, Min, Nassour, Ibrahim, Ju, Michelle R., Xiao, Shu, Castro‑Dubon, Esther C., Agrawal, Deepak, Suarez, Jorge, Reznik, Scott I., Mansour, John C., Polanco, Patricio M., Yopp, Adam C., Zeh III, Herbert J., Hwang, Tae Hyun, Zhu, Hao, Porembka, Matthew R., and Wang, Sam C.

Published
2024
Full Text
View/download PDF

6. Diagnostic laparoscopy is underutilized in the staging of gastric adenocarcinoma regardless of hospital type: An US safety net collaborative analysis

Author

Macek, Aleeza J Leder, Wang, Annie, Turgeon, Michael K, Lee, Rachel M, Russell, Maria C, Porembka, Matthew R, Alterio, Rodrigo, Ju, Michelle, Kronenfeld, Joshua, Goel, Neha, Datta, Jashodeep, Maker, Ajay V, Fernandez, Manuel, Richter, Harry, Berman, Russell S, Correa‐Gallego, Camilo, and Lee, Ann Y

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Digestive Diseases, Cancer, Clinical Research, Rare Diseases, Patient Safety, No Poverty, Adenocarcinoma, Hospitals, Humans, Laparoscopy, Neoplasm Staging, Retrospective Studies, Stomach Neoplasms, diagnostic laparoscopy, disparities, gastric adenocarcinoma, safety net hospital, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundDiagnostic laparoscopy (DL) is a key component of staging for locally advanced gastric adenocarcinoma (GA). We hypothesized that utilization of DL varied between safety net (SNH) and affiliated tertiary referral centers (TRCs).MethodsPatients diagnosed with primary GA eligible for DL were identified from the US Safety Net Collaborative database (2012-2014). Clinicopathologic factors were analyzed for association with use of DL and findings on DL. Overall survival (OS) was analyzed by Kaplan-Meier method.ResultsAmong 233 eligible patients, 69 (30%) received DL, of which 24 (35%) were positive for metastatic disease. Forty percent of eligible SNH patients underwent DL compared to 21.5% at TRCs. Lack of insurance was significantly associated with decreased use of DL (OR 0.48, p

Published
2022

7. Attrition during neoadjuvant chemotherapy for gastric adenocarcinoma is associated with decreased survival: A United States Safety‐Net Collaborative analysis

Author

Kronenfeld, Joshua P, Collier, Amber L, Turgeon, Michael K, Ju, Michelle, Alterio, Rodrigo, Wang, Annie, Fernandez, Manuel, Porembka, Matthew R, Richter, Harry, Lee, Ann Y, Russell, Maria C, Merchant, Nipun B, Maker, Ajay V, and Datta, Jashodeep

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Patient Safety, Cancer, Digestive Diseases, Evaluation of treatments and therapeutic interventions, 6.4 Surgery, Activities of Daily Living, Adenocarcinoma, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoadjuvant Therapy, Prognosis, Retrospective Studies, Stomach Neoplasms, Survival Rate, Young Adult, completion of therapy, gastric cancer, neoadjuvant therapy, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundNeoadjuvant chemotherapy (NAC) is standard management for localized gastric cancer (GC). Attrition during NAC due to treatment-related toxicity or functional decline is considered a surrogate for worse biologic outcomes; however, data supporting this paradigm are lacking. We investigated factors predicting attrition and its association with overall survival (OS) in GC.MethodsPatients with nonmetastatic GC initiating NAC were identified from the US Safety-Net Collaborative (2012-2014). Patient/treatment-related characteristics were compared between attrition/nonattrition cohorts. Cox models determined factors associated with OS.ResultsOf 116 patients initiating NAC, attrition during prescribed NAC occurred in 24%. No differences were observed in performance status, comorbidities, treatment at safety-net hospital, or clinicopathologic factors between cohorts. Despite absence of distinguishing factors, attrition was associated with worse OS (median: 11 vs. 37 months; p = 0.01) and was an independent predictor of mortality (hazard ratio [HR]: 4.7, 95% confidence interval [CI]: 1.5-15.2; p = 0.02). Fewer patients with attrition underwent curative-intent surgery (39% vs. 89%; p

Published
2021

8. Clinical Presentation Patterns and Survival Outcomes of Hispanic Patients with Gastric Cancer

Author

Vitiello, Gerardo A, Hani, Leena, Wang, Annie, Porembka, Matthew R, Alterio, Rodrigo, Ju, Michelle, Turgeon, Michael K, Lee, Rachel M, Russell, Maria C, Kronenfeld, Joshua, Goel, Neha, Datta, Jashodeep, Maker, Ajay V, Fernandez, Manuel, Richter, Harry, Correa-Gallego, Camilo, Berman, Russell S, and Lee, Ann Y

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Digestive Diseases, Patient Safety, Rare Diseases, Cancer, Clinical Trials and Supportive Activities, Health Services, Clinical Research, No Poverty, Ethnicity, Hispanic or Latino, Humans, Middle Aged, Neoplasm Staging, Retrospective Studies, Stomach Neoplasms, Gastric cancer, Hispanic, Safety-net, Survival, Clinical Sciences, Surgery, Clinical sciences
Abstract

BackgroundHispanic patients have a higher incidence of gastric cancer when compared to non-Hispanics. Outlining clinicodemographic characteristics and assessing the impact of ethnicity on stage-specific survival may identify opportunities to improve gastric cancer care for this population.MethodsPatients with gastric cancer in the US Safety Net Collaborative (2012-2014) were retrospectively reviewed. Demographics, clinicopathologic characteristics, operative details, and outcomes were compared between Hispanic and non-Hispanic patients. Early onset gastric cancer was defined as age

Published
2021

9. Is there a difference in utilization of a perioperative treatment approach for gastric cancer between safety net hospitals and tertiary referral centers?

Author

Turgeon, Michael K, Lee, Rachel M, Keilson, Jessica M, Ju, Michelle R, Porembka, Matthew R, Alterio, Rodrigo E, Kronenfeld, Joshua, Datta, Jashodeep, Goel, Neha, Wang, Annie, Lee, Ann Y, Fernandez, Manuel, Richter, Harry, Maker, Ajay V, Maithel, Shishir K, and Russell, Maria C

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Cancer, Clinical Research, Digestive Diseases, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Aged, Female, Follow-Up Studies, Gastrectomy, Humans, Male, Middle Aged, Neoadjuvant Therapy, Perioperative Care, Prognosis, Quality of Health Care, Retrospective Studies, Safety-net Providers, Stomach Neoplasms, Tertiary Care Centers, gastric cancer, health disparities, perioperative therapy, safety net hospitals, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

Background and objectivesPerioperative therapy is a favored treatment strategy for gastric cancer. We sought to assess utilization of this approach at safety net hospitals (SNH) and tertiary referral centers (TRC).Materials and methodsPatients in the US Safety Net Collaborative (2012-2014) with resectable gastric cancer across five SNH and their sister TRC were included. Primary outcomes were receipt of neoadjuvant chemotherapy (NAC) and perioperative therapy.ResultsOf 284 patients, 36% and 64% received care at SNH and TRC. The distribution of Stage II/III resectable disease was similar across facilities. Receipt of NAC at SNH and TRC was similar (56% vs. 46%, p = 0.27). Compared with overall clinical stage, 38% and 36% were pathologically downstaged at SNH and TRC, respectively. Among patients who received NAC, those who also received adjuvant chemotherapy at SNH and TRC were similar (66% vs. 60%, p = 0.50). Asian race and higher clinical stage were associated with receipt of perioperative therapy (both p

Published
2021

25. Lenvatinib inhibits the growth of gastric cancer patient-derived xenografts generated from a heterogeneous population

Author

Karalis, John D., Yoon, Lynn Y., Hammer, Suntrea T. G., Hong, Changjin, Zhu, Min, Nassour, Ibrahim, Ju, Michelle R., Xiao, Shu, Castro-Dubon, Esther C., Agrawal, Deepak, Suarez, Jorge, Reznik, Scott I., Mansour, John C., Polanco, Patricio M., Yopp, Adam C., Zeh, III, Herbert J., Hwang, Tae Hyun, Zhu, Hao, Porembka, Matthew R., and Wang, Sam C.

Published
2022
Full Text
View/download PDF

34. Intensifying supportive care is associated with improved survival in gastric cancer patients with malignant ascites

Author

Karalis, John D., primary, Ju, Michelle R., additional, Feig, Rachel, additional, Estrella, Raechelle, additional, Pettigrew, Morgan F., additional, Alterio, Rodrigo E., additional, Abreu, Andres A., additional, Farah, Emile, additional, Sawas, Tarek, additional, Sanford, Nina N., additional, Sanjeevaiah, Aravind, additional, Hammer, Suntrea T. G., additional, Porembka, Matthew R., additional, and Wang, Sam C., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results